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A B S T R A C T
Understanding the protein-secretion dynamics from single, speciﬁc tissues is critical toward the advancement of
disease detection and treatments. However, such secretion dynamics remain diﬃcult to measure in vivo due to
the uncontrolled contributions from other tissue populations. Here, we describe an integrated platform designed
for the reliable, near real-time measurements of cytokines secreted from an in vitro single-tissue model. In our
setup, we grow 3D biomimetic tissues to discretize cytokine source, and we separate them from a magnetic
microbead-based biosensing system using a Transwell insert. This design integrates physiochemically controlled
biological activity, high-sensitivity protein detection (LOD < 20 pgmL−1), and rapid protein diﬀusion to enable
non-invasive, near real-time measurements. To showcase the speciﬁcity and sensitivity of the system, we use our
setup to probe the inﬂammatory process related to the protein Interleukine 6 (IL-6) and to the Tumor Necrosis
Factor (TNF-α). We show that our setup can monitor the time-dependence proﬁle of IL-6 and TNF-α secretion
that results from the electrical and chemical stimulation of 3D skeletal muscle tissues. We demonstrate a novel
and aﬀordable methodology for discretizing the secretion kinetics of speciﬁc tissues for advancing metabolic-
disorder studies and drug-screening applications.
1. Introduction
Detecting changes in protein secretion with spatiotemporal accu-
racy remains a fundamental challenge toward understanding the role of
proteins in regulating biological processes. For instance, to understand
its role in immune and inﬂammatory responses, (Rothenberg, 2007)
protein expressions of cytokine are routinely studied from blood serums
using methods such as RNA sequencing, protein microarrays, enzyme-
linked immunosorbent assay (ELISA) or mass spectroscopy (MS)
(Mukherjee and Mani, 2013). However, because most in vivo tissues of
interest are composed of a variety of cells, proﬁling cytokine expres-
sions by speciﬁc cells directly from bulk serum samples remains im-
practical.
Recent studies approach this challenge in two ways, focusing either
on maximizing detection sensitivity, or on tailoring the ideal functional-
tissue models. The ﬁrst approach targets real-time analysis and quan-
tiﬁcation of secreted cytokines using ultrasensitive detection method or
imaged-based high-resolution spatiotemporal techniques (Shirasaki
et al., 2015; Juan-Colás et al., 2018; Saxena et al., 2018). Here however,
because the techniques involved rely on single-cell secretion, this ap-
proach cannot probe cytokine secretion by functional tissues.
The second approach tailors speciﬁc, desired functional tissue
samples that can be probed by established techniques such as ELISA or
MS. Using this approach, cytokine secretions have been analyzed from
in vivo muscles, in vitro contractile myoﬁber sheets, (Furrer et al.,
2017; Takahashi et al., 2018) or even adipose and immune cells co-
cultures without unwanted interactions from unknown cells
(Kongsuphol et al., 2019). However, because techniques such as ELISA
and MS lack temporal resolution, this approach cannot proﬁle cytokine
secretion at timescales relevant to biological processes (Zhang et al.,
2017; Bruls et al., 2009; Esteban-Fernández de Ávila et al., 2013;
Skardal et al., 2017). Here we present an integrated platform designed
for reliable, near real-time proﬁling of cytokine secretions by com-
bining the advantages of both aforementioned approaches: we max-
imize both the chemical and the time resolution of our detection
system, and we tailor tissue samples that are ideal for our measurement.
Fig. 1 illustrates our integration concept, which grows the desired 3D
skeletal muscle (SM, blue oblongs) sample tissues on the top surface of
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the porous membrane (dashed lines) of a Transwell insert, in proximity
of antibody-bioconjugated magnetic microbead (MB·abs) detectors, lo-
cated underneath the membrane. Upon electrical and chemical stimu-
lation applied to the SM in the Transwell insert, any secreted cytokine
would rapidly diﬀuse through the porous membrane to be captured by
the nearby microbeads. This concept enables our custom-grown in vitro
3D SM tissues (Ortega et al., 1039) to provide the ideal sample for our
measurements, while exploiting the magnetic beads’ high area to vo-
lume ratio and its proximity to the sample maximize chemical and
temporal resolutions (20 and 10 pgmL−1, near real-time, respectively).
In this article, we test the validity of our concept by proﬁling in-
ﬂammatory process related cytokines: Interleukine 6 (IL-6) and Tumor
Necrosis Factor (TNF-α), induced by chemical and electrical stimula-
tion of 3D engineered skeletal muscle tissues. We demonstrate that our
integrated system represents a simple and feasible tool proﬁling the
secretion kinetics of speciﬁc proteins from speciﬁc in vitro tissue
models. Our results provide a new strategy toward understanding the
role of proteins in both diseased and healthy states and in drug-
screening assays.
2. Experimental section
2.1. Materials
Electrochemical measurements were carried out using a Portable
multipotentiostat μSTAT 8000P (Metrohm Dropsense AG Herisau,
Switzerland)). Screen-printed carbon electrodes (SPCEs), were in-
tegrated by a Ag/AgCl pseudo-reference electrode and a carbon counter
electrode (DRP-8X110, 2.56mm Ø) originally used as working elec-
trodes (Metrohm Dropsense AG Herisau, Switzerland). Round bottom
non-treated plates were purchased from Nirco (Barberà del Vallés,
Spain). Polystyrene MaxiSorp microtiter plates used to perform ELISA
assays were purchased from Nunc (Roskilde, Denmark). Washing steps
were carried out using a 405 TS microplate washer (BioTeck
Instruments, Winooski, USA). The electrochemical data obtained was
analyzed using DropView 8400 software (Metrohm Dropsense AG
Herisau, Switzerland). Absorbances were read on Inﬁnite® 200 PRO
multiplate reader (TEKAN, Männedorf, Switzerland). Digital light
processing (DLP) projector-based stereo-lithography 3D printer (Solus
DLP model, Reify3D, CA, USA) was used to fabricate the device for the
electrical stimulation. Crosslinking of composite hydrogel were per-
formed by a UVP Crosslinker (CL-1000, Analytik Jena, Germany).
Assessment of electrical stimulation was done using grade 1 graphite
Rods (Ted Pella, Ca, USA), connected to a multifunctional wave gen-
erator (WF1947/WF1948, NF corporation, Japan).
2.1.1. Chemicals and immunochemicals
Recombinant mouse Interleukin 6 (ref. 200-02-100 μg) and re-
combinant mouse TNF-α (ref. 200-31-100 μg) were purchased from
CliniSciences S.L. (Nanterre, France). Puriﬁed rat anti-mouse IL-6 (ref.
554400, clone MP5-20F3, capture antibody), biotin rat anti-mouse IL-6
(ref. 554402, clone MP5-32C11, detection antibody), puriﬁed rat anti-
mouse TNF-α (ref. 551225, clone G281-2626, capture antibody), and
biotin rat anti-mouse TNF-α (ref. 554415, clone MP6-XT3, detection
antibody) were purchased from BD Biosciences (Barcelona, Spain).
Streptavidin-poly Horseradish Peroxidase (SAV-pHRP), MF20 Alexa
Fluor 488, DAPI, Tosyl-activated magnetic beads MB Dynabeads®
MyOne™, Dulbecco's modiﬁed Eagle's medium (DMEM high glucose, L-
glutamine, GIBCO, 11965092)), trypsin/EDTA, horse serum (HS,
26050088), fetal bovine serum (FBS, 16000044), penicillin/strepto-
mycin (P/S, 15140122), 3.5 kDa MWCO membranes (68035) were
purchased from Thermo Fisher (21140, Massachusetts, USA). Bovine
serum albumin (BSA, A4737), Dexamethasone (Dex, D4901), Caﬀeine
(C0750) and Lipopolysaccharides from E. Coli O55:B5 (LPS, L6529),
Gelatin Type A from porcine skin (G2500), methacrylate anhydride
(276685), 10% formalin solution (HT5011), Triton (X-100), 24mm
Transwell with 0.4 μm Pore Polyester Membrane Insert (CLS3450),
Sodium carboxymethylcellulose (CMC, 419273), N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC,
E7750), N-hydroxysuccinimide (NHS, 130672), aminoethylmethacry-
late (479659), Trypsin/EDTA (T4049) were purchased from Sigma-
Aldrich (Sigma Aldrich Co. St Louis. MO, USA). Tris-buﬀered saline was
purchased from Canvax (TBS, BR0042, Biotech, Spain). Rhodamine-
Phalloidin 480 was purchased from Cytoskeleton (PHDR1, USA). The
Bradford solution (BIO-RAD protein assay cat No. 500-0006) was pur-
chased from BIO-RAD laboratories GmbH (Munich, Germany). Acetone
Fig. 1. Schematic illustration of the immunosensor measurement procedure. Firstly, 3D SM is fabricated on the Transwell membrane, then MB·Abs are loaded in
the lower compartment. Secreted cytokines, under the chemical and electrical eﬀect, are captured by the MB·Abs. Detection step is followed by the addition of a
biotinylated antibody and SAV-pHRP. Finally, MB·Abs are resuspended in enzymatic buﬀer and captured on the surface of the SPCEs. After addition of the corre-
sponding substrate, EC signal is obtained. The intensity of the current is directly related with the concentration of secreted cytokines.
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was purchased from Panreac (161007, Barcelona, Spain).
Polydimethylsiloxane (PDMS) was purchased from Dow Corning
(SILPOT 184, Toray, Japan). 6–8 kDa MWCO membranes were pur-
chased from Spectrumlabs (08-700-142, San Francisco, USA). Lithium
Phenyl (2,4,6-trimethylbenzoyl)phosphinate (i.e., LAP) was purchased
from TCI EUROPE N.V. (Belgium). Murine C2C12 skeletal myoblasts
was purchased from American Type Culture Collection (CRL-1772,
ATCC, Virginia, USA). Phosphate buﬀer saline (PBS) was 0.01mol L−1
phosphate buﬀer, 0.14mol L−1 in NaCl and 0.003mol L−1 in KCl saline
solution at pH 7,5. PBST was PBS with 0.05% (v/v) Tween 20. PBST-
BSA was PBST with 1% (w/v) BSA. Coating buﬀer is 0.05M carbonate-
bicarbonate buﬀer, pH 9.6. Citrate buﬀer was a 0.04M solution of so-
dium citrate, pH 5,5. The substrate solution for optical measurement
and used also in the amperometric immunosensor was 0.01% TMB
(3,3′,5,5′-tetramethylbenzidine) and 0.004% H2O2 in citrate buﬀer.
For amperometric measurements, citrate buﬀer-KCl was prepared with
citrate buﬀer that contains 0.1mol L−1 KCl. Borate buﬀer was 0.1 M
boric acid (pH 9.5).
2.2. Preparation and optimization of the MB·Abs-based immunosensing
platform
The antibody was coupled covalently to the magnetic beads
(Supplementary information) according to the supplier protocol but
with slight modiﬁcations, and the ﬁnal concentration of the functio-
nalized microbeads (MB·Abs) was 8mgmL−1. Prior to performing the
detection of the secreted cytokines, the immunosensing platform was
characterized and optimized (in terms of concentration) by checkboard
titration. The incubation time for cytokines detection by MB·Abs was set
at 60min. Subsequent incubation steps for biotinylated antibody and
SAV-pHRP bioconjugate were set at 30min. Interleukin 6 and TNF-α
solutions were prepared at 4 ngmL−1 in diﬀerentiation media as
standard solutions during amperometric optimization measurements.
The eﬀects of diﬀerent parameters, including the MB·Abs quantity,
biotinylated antibody, and enzyme tracer concentrations, were ana-
lyzed. The eﬀect of each parameter was evaluated individually, and
optimized values were used in subsequent experiments. Initially,
MB·Abs quantity was optimized in the range of 0.1 μg–5 μg. Other
parameters including biotinylated antibody and SAV-pHRP concentra-
tions were maintained constant at 1 μgmL−1 in both cases.
To optimize detection and enzymatic steps, MB·Abs concentration
was set, and concentrations of both biotinylated antibodies and SAV-
pHRP were evaluated in the range of 0.0625–1 μgmL−1, following the
same procedure as described before.
Related to selectivity studies, cross-reactivity was evaluated for ei-
ther IL-6 and TNF-α including a negative control (zero point). On the
other hand, to evaluate accuracy in our experiments, diﬀerent blind
spiked samples were prepared in diﬀerentiation media and measured
directly by our optimized immunoassays. Accuracy for both im-
munoassays was evaluated by establishing a linear regression between
spiked and measured values. All experiments were performed in tri-
plicate.
2.3. Cell culture
Murine C2C12 myoblast cells were cultured under a 5% CO2 at-
mosphere at 37 °C in growth medium, high glucose DMEM, containing
L-Glut, 10% (v/v) FBS, 1% (v/v) P/S. When ∼70% conﬂuency was
reached, the cells were detached by using trypsin/EDTA and then
subcultured or used in the experiment. High glucose DMEM, containing
L-Glut, 2% (v/v) HS, and 1% (v/v) P/S was used as diﬀerentiation
medium (DM) to promote C2C12 diﬀerentiation towards myotubes.
2.4. Synthesis and preparation of prepolymer solutions
Gelatin-methacryloyl (GelMA) and carboxymethyl cellulose-
methacrylate (CMCMA) were synthesized according with our previous
reported protocol (Supporting Information) (García-lizarribar et al.,
2018). Prepolymer solutions were prepared by dissolving polymers and
photoinitiator lithium phenyl (2,4,6-trimethylbenzoyl)phosphinate
(LAP) in growth medium to obtain ﬁnal concentrations of 5% (w/v)
GelMA, 1% (w/v) CMCMA, and 0.1% (w/v) LAP. Prepolymer solutions
were placed at 65 °C for 3 h to obtain homogeneous solutions.
2.5. Fabrication of the 3D SM engineered tissue (3SM)
Polymer solution was mixed with a C2C12 cell suspension to reach
the ﬁnal cell density of 25·106 cell mL−1. 3D skeletal muscle tissues
were fabricated by photo-molding technique as we described previously
(Ortega et al., 1039). Brieﬂy, 20 μL of the cell-laden prepolymer were
poured on the Transwell insert (24mm) and a microstructured PDMS
stamp was placed onto the prepolymer. The PDMS microgrooves were
ﬁlled and cell-laden prepolymer was exposed for 24 s under a UV light
source (40W, UVP Crosslinker) (Fig. S2, Supplementary information).
After carefully removing the stamp we obtained a 3D cell-micro-
structured hydrogel anchored on the Transwell membrane. Once 3SM
was fabricated, a new cell medium was added on the upper part (1 mL)
and the lower part (2 mL) and changed every 2 days. The growth
medium was replaced at day 6 with diﬀerentiation media (DM). The
DM was changed every 2 days until day 14, when the drug assays or
electrical assays were carried out.
2.6. Immunostaining
The tissues were ﬁxed in a 10% formalin solution at 15 days after
fabrication. Then hydrogels were washed with TBS, cells were per-
meabilized with 0.1% Triton X- 100 in TBS for 15min and blocked with
a blocking buﬀer consisting of 0.3% Triton X- 100 and 3% donkey
serum (brand) in TBS for 2 h. Afterwards, tissues were washed with TBS
and incubated in 100 nM Rhodamine-Phalloidin 480 solution overnight
to stain ﬁlamentous actin (F-actin). An additional overnight staining for
Myosin Heavy Chain (MHC) was performed by incubating in a solution
of 5 μg/mL MF20 Alexa Fluor 488 in blocking buﬀer. After washing
with TBS, nuclei were counterstained with DAPI 1 μM for 15min.
2.7. Immunosensor measurement procedure
Transwell permeable supports were used as a platform to develop
the immunosensing measurement procedure, design and operation of
the integrated platform is depicted in Fig. 1. 3SM were maintained in
culture for up to 14 days and, just before electrical or chemical sti-
mulation, MB·Abs (5 μg for IL-6 and 10 μg for TNF-α) were loaded in the
lower side of the Transwell, where capture step was performed. Sam-
ples were incubated under soft stirring to avoid bead aggregation, in-
side an incubator at 37 °C and 5% CO2 atmosphere. During the ex-
periments, upper part and lower part was ﬁlled with 1mL and 2mL of
cell medium, respectively. Secreted cytokines, as a result of either
electrical or chemical stimulation, diﬀused trough the Transwell
membrane and were captured by the speciﬁc antibodies immobilized
onto the surface of the beads. MB·Abs were replaced every hour to
obtain a continuous monitoring of the secreted cytokines. After this
time, MB·Abs were washed (3X) and resuspended in biotinylated anti-
body 0.125 μgmL−1 or 0.5 μgmL−1 (in the case of IL-6 or TNF-α re-
spectively), prepared in PBST-BSA buﬀer, and leave it under stirring for
30min to avoid bead aggregation. Then, MB·Abs were washed again
and resuspended in SAV-pHRP 0.50 μgmL−1 (for both cytokines) pre-
pared in PBST-BSA buﬀer, for 30min under the same conditions de-
scribed before. Afterwards, MB·Abs were washed and resuspended in
100 μL of citrate buﬀer-KCl and captured onto the surface of the
working electrode using a custom-made PMMA cell with magnets lo-
cated under the SPCEs (Fig. S3 Supporting Information). Finally, am-
perometric measurements were carried out by applying a constant
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potential of −0.2 V vs Ag pseudo-reference electrode. After current
stabilization (100 s), 20 μL of substrate solution prepared in citrate
buﬀer-KCl, was added to each well. Electrochemical signals were re-
corded once the current was again stabilized (250 s).
2.8. Drug stimulation assays
2D Drug stimulation screening assays. Caﬀeine, Dexamethasone (Dex)
and Lipopolysaccharide (LPS) were tested in skeletal myotubes cultured
in 2D (well plate conﬁguration) using diﬀerentiation media for 7 days,
to evaluate the eﬀect of each drug in the cytokine's secretion at diﬀerent
times. Myotubes cultured in 2D were incubated for 0.5, 1, 2, 16, 24 and
48 h, in DM supplemented by the drug. Caﬀeine was diluted in DM to a
concentration of 100 μM. Dex, was suspended in absolute ethanol at a
concentration of 10mM and diluted further in DM to obtain a ﬁnal
concentration of 100 μM. LPS was diluted in DM to a concentration of
10 μgmL−1. Three replicas for each condition were analyzed. The
screening of the cytokine levels was carried out by ELISA (See sup-
porting information).
3SM drug stimulation assay.Mature 3SM at day 14 were incubated in
DM supplemented by LPS at diﬀerent times: 0.5, 1, 2, 4, 8 and 24 h.
MB·Abs were placed 1 hour before drug treatment in the lower com-
partment, and after drug treatment the immunoassay was performed as
described in section 2.8.
2.9. Electrical pulse stimulation (EPS) assays
In order to stimulate 3SM on the Transwell membrane, a pair of
graphite electrodes (3mm diameter), separated at 1 cm, were used. A
custom-made device was designed and fabricated using a DLP pro-
jector-based stereo-lithography 3D printer to hold the electrodes and
ﬁxed on well plate's lid. Copper wires were assembled to graphite rods
and located out of the lid through the device, to permit the connection
to a wave generator (Supplementary information). Under this conﬁg-
uration, electrical stimulation on Transwells was carried out in a high
reproducible way, allowing the microscope imaging of the tissue.
Mature 3SM were subjected to stimulations regimes with 0.25, 1 and
5 V peak-peak at 1 Hz of frequency and a duration of 2ms during 1 h, to
evaluate cell response upon electrical stimuli. To study time-dependent
secretion of cytokines, samples were stimulated for seven hours in a
continuous EPS, and on the other hand in cycles of 1 h stimulation with
and 2 h of relaxing time (stimulation oﬀ) for a total of nine hours.
2.10. Data and statistical analysis
The calibration curves ﬁttings and statistical analysis were per-
formed using GraphPad Prims 5.03 (GraphPad Software Inc., San
Diego, CA). Data is presented as the mean (⨱ ± SD). A t-test was used
for statistical analysis of two sample comparison, and ANOVA one-way
for statistical evaluation of one factor. A value of p < 0.05 was con-
sidered statistically signiﬁcant.
3. Results and discussion
3.1. Immunoassay optimization and analytical features
The conjugation eﬃciency (coupling of antibody to MB) super-
natants after immobilization process were evaluated using Bradford
assay. Our results indicate a coupling yield of 94 ± 8% for all re-
plicates. The functionality of the bioconjugates by the electrochemical
immunoassay, MB·Abs, biotinylated antibody, and SAV-pHRP con-
centracions were optimized by checkboard titration assay. Fig. 2a il-
lustrates the eﬀect of MB·Abs quantity on the normalized current ob-
tained at −0.2 V applied potential, corresponding to IL 6 (orange
circle) and TNF-α (blue squares) detection. The current reaches op-
timum signal at 5 μg (IL-6) and 10 μg (TNF-α) of MB·Abs, with non-
signiﬁcant enhancement of the signal using higher concentrations.
These values of MB·Abs were selected for the optimization of the further
steps.
Fig. 2b shows the values of the maximum signal performance
achieved at diﬀerent biotinylated antibody concentrations. The current
values for IL-6 reach saturation point at 0.125 μgmL−1 of biotinylated
antibody, while for TNF-α we consider the saturation level above
0.5 μgmL−1, setting these values as optimal for further experiments.
Finally, the current response was tested at diﬀerent concentrations
of SAV-pHRP, from 0.0625 to 1 μgmL−1. As shown in Fig. 2c, in the
case of IL-6, the signal response shows an increment of 50% μA at
0.5 μgmL−1, whereas in the case of TNF-α, this improvement takes
place at a lower concentration of 0.25 μgmL−1, maintaining the same
response at higher concentrations of the SAV-pHRP. For these reasons,
concentration of 0.5 μgmL−1 of SAV-pHRP for both immunoassays
were selected, simplifying the experimental procedure of the biosensor
for both cytokines. These optimized values were used in later de-
termination of calibrations curves, which represent the working con-
ditions to obtained lowest limit of detection.
The dose-dependence of the magnetic bead-based immunosensors
developed was studied for diﬀerent concentrations of IL-6 and TNF-α in
diﬀerentiation media. The assay was performed as is shown in Fig. 1,
and described in Section 2, by assessing standard solutions of IL-6 and
TNF-α (between 0 and 0.5 ngmL 1 in DM). As expected, the current
signal recorded was directly proportional to the concentration of the
cytokine in the sample in both cases. The limit of detection for IL-6 and
TNF-α (Fig. 2d and e) were 40 ± 10 pgmL−1 and 20 ± 10 pgmL−1,
respectively, which are better than ELISA tests.
Several works that have used magnetic beads to detect secreted
biomarkers or cytokines have reported similar LOD's, about tens of pg
mL−1. Riahi et al. succeeded on on-chip measurements with a LOD of
30 pgmL−1 by EC detection (Riahi et al., 2016). Other reports are based
on the use of on-chip ﬂuorescent bead-based immunoassay, (Cui et al.,
2018) or by magnetic beads with the out-chip enzymatic step to
monitor cytokine secretion from immune cells with a sensitivity of tens
of pg mL−1 (Kongsuphol et al., 2016). Also, by a novel optoﬂuidic
nanobiosensor, Li et al., have reported a sensitivity of 39 pgmL−1, in
the real-time detection of cytokine secretion using nanoplasmonics (Li
et al., 2018). Thus, the limit of detection reached by the immunosensor
described in this work is considered optimal for our purposes, taking
into account the sensitivity reported by recent works, and the reported
amount of secreted IL-6 (∼0.05 ngmL−1) without any stimulation in
skeletal muscle 2D cultures (Nedachi et al., 2008; Farmawati et al.,
2013). Our selectivity studies showed no cross reactivity between IL-6
and TNF-α and the feasibility of the system, while the assays used to
study the accuracy in both cases showed a slope close to 1 (Fig. 3f and
g), indicating that both immunosensors are high accurate in the
working range of our interest.
3.2. 3D SM engineered tissue (3SM) and sensing system integration
To fabricate the 3D skeletal muscle constructs, muscle cells were
encapsulated in a 5% w/v Gelatin methacryloyl (GelMA), and 1% w/v
carboxy methyl cellulose methacrylate (CMCMA) polymer solution.
Gelatin methacryloyl was combined with CMCMA to avoid cell de-
gradation and improve stability, as we previously demonstrated
(García-lizarribar et al., 2018). To control the 3D cellular organization
of the encapsulated C2C12 cells, photo-mold patterning technique was
applied using a microgrooved PDMS stamp and this method was di-
rectly carried out on the upper membrane of a Transwell (Fig. 3a–e).
(Ortega et al., 1039)
The skeletal muscle constructs were diﬀerentiated from day 6 to day
14 and characterized by bright ﬁeld microscopy during the skeletal
muscle cells maturation. At day 14 constructs show aligned ﬁbers
(Fig. 3f), which compared to non-patterned samples show a high degree
of alignment (Fig. 3g). The myotubes show a high content of myosin
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heavy chain positive stained cells (Fig. 3h), and a high fusion index
compared to non-patterned samples (Fig. 3i). Thus, these results de-
monstrate the functional C2C12 diﬀerentiation towards myotubes and
are in concordance with found by Ortega et al. (Ortega et al., 1039) We
demonstrate that the reported fabrication method can be used on a
permeable membrane without further modiﬁcations, and 3SM kept
anchored on the membrane for at least 14 days supporting growth and
skeletal muscle diﬀerentiation. In the present work, we exploit the
advantages of Transwell insert membranes, to assess the invasive way
of place MB·Abs and 3SM together. To demonstrate cytokine diﬀusion
through the Transwell membrane (0.4 μm pore size), we placed IL-6
solution in the upper compartment. As expected, we found that IL-6
concentration increases with time in the lower compartment, indicating
diﬀusion of cytokines through the porous membrane. Thus, permeable
membranes, where 3SM are located, allow the diﬀusion of the secreted
cytokines to the lower compartment where MB·Abs immediately cap-
ture the cytokines, but the membrane pore size prevents MB·Abs dif-
fusion to the upper part. In this work, the integrated platform has been
designed to monitor the secretion processes over time by the in situ
capturing of the released cytokines. Several works have previously used
complex chip arrays or devices to detect cytokines from immune cells
by MB·Abs, which were located in separated compartments or chambers
to avoid the cell-MB·Abs interaction (Riahi et al., 2016; Cui et al., 2018;
Kongsuphol et al., 2016). In addition, previous work has reported
complex systems based on ﬂuorescence imaging or nanoplasmonic
biosensors, which capture antibodies on the substrate for detecting
cytokine secretion of single cells (Juan-Colás et al., 2018; Li et al., 2018;
Nedachi et al., 2008; Farmawati et al., 2013; An et al., 2017). These
examples have succeeded in “real-time” quantiﬁcation of cytokine se-
cretion but using single cells or cell solutions. Our platform in-
corporates the novelty of integrating a 3D tissue-like skeletal muscle
instead of isolated cells.
3.3. Drug stimulation assays
To study the viability of the sensor and monitor the response of the
skeletal muscle against chemical stimuli, IL-6 and TNF-α secretion were
measured. To ﬁnd the best chemical stimuli for promoting IL-6 secre-
tion, 2D monolayers of diﬀerentiated myotubes were incubated with
caﬀeine, which causes eﬀects on muscle size and changes in signaling
Fig. 2. Optimization of the electrochemical MB·Abs based immunoassay for IL-6 (orange circles) and TNF-α (blue squares) using 4 ngmL−1 of each
cytokine. Normalized current vs a) the number of microbeads in the 6 well Transwell set up, b) concentration of the biotinylated antibody, and c) SAV-pHRP
concentration. Other parameters such as cytokine concentration and incubation time for each step were maintained ﬁxed. Calibration curves for the detection of d)
IL-6 and e) TNF-α respectively, in diﬀerentiation media and diﬀerent analytical parameters such as limit of detection and quantiﬁcation. f) Selectivity studies for both
immunoassays, IL-6 and TNF-α at concentration of 4 ngmL−1. g) Accuracy studies performed using spiked samples prepared in diﬀerentiation media and used
directly in the immunosensor without previous dilution. The data shown correspond to the average of at least two replicates. All data shown by mean ± SD. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the Web version of this article.)
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pathways, (Egawa et al., 2016) dexamethasone, which is used as a
muscle atrophy inducer, (Shimizu et al., 2017) and LPS which stimu-
lates the expression of IL-6 and TNF-α in both skeletal muscles in vivo
and C2C12 myoblasts in vitro (Frost et al., 2002).
After we determined cytokine secretion by a in house ELISA, LPS
treatment showed the highest secretion of IL-6 with no signiﬁcant
changes under caﬀeine and Dex treatment (Fig. 4a and b). The TNF-α
values do not show signiﬁcant changes under all the treatments (Fig. 4c
and d). Thus, LPS was chosen to be tested in the integrated sensing
system.
The 3D skeletal muscle tissues were grown on the Transwell mem-
brane and at day 14 and incubated with diﬀerentiation media con-
taining LPS (10 μgmL−1). The IL-6 and TNF-α secretions were mon-
itored in function of time for 24 hours. The IL-6 secretion showed an
increasing proﬁle along the incubation time as was found in 2D ex-
periments. The TNF-α secretion showed an increasing but no statisti-
cally signiﬁcant trend, and released less protein compared to IL-6
(Fig. 4e and f).
Our results prove that 3SM responds to LPS treatment, and that
mature muscle cells secrete IL-6. On the other hand, we have demon-
strated the capacity of the integrated system to monitor low con-
centrations of cytokine levels, immediately following chemical stimuli.
After 24 h, we found that the IL-6 expression fold change
(20.98 ± 1.61) was at least three times higher than the TNF-α fold
change (3.37 ± 4.00); this correlates with the reported diﬀerences
between IL-6 and TNF-α expression under LPS treatment in mouse
(Frost et al., 2002).
3.4. Dependence between contraction/relaxation periods and IL-6 secretion
from skeletal muscle
To electrically stimulate the 3SM, we designed and fabricated a
device that ﬁts in the Transwell insert containing a pair of graphite rods
(Fig. 5a). A function generator was connected to the graphite rods by
copper wires in the external part of the well plate's lid (Fig. 5b). The
graphite rods are not in direct contact with the 3SM, enabling the
Fig. 3. Fabrication of the 3D skeletal muscle in the integrated platform. a) Schematics of the photo mold patterning on the Transwell. 1. A drop of cell-laden solution
is poured on the porous membrane of the Transwell, 2. A microstructured PDMS stamp is placed onto the prepolymer. The PDMS microgrooves were ﬁlled and cell-
laden prepolymer is exposed under a UV light. 3. After removing the stamp we obtain a 3D cell-microstructured hydrogel anchored on the Transwell membrane. 4.
After 14 days we obtain a mature 3D skeletal muscle. Pictures of the fabrication process: b) Cell-laden prepolymer drop onto a Transwell. c) Detail of the micro-
grooved stamp. d) PDMS microgrooves ﬁlled with the prepolymer cell-laden solution. e) Detail of the skeletal muscle tissue (arrow) on the Transwell, after fabri-
cation. f) Confocal microscopy picture of 3SM at say 14, showing elongated cells and myotubes. F-actin in red. Scale bar = 500 μm. g) Normalized histogram
(bin = 15°) depicting the distribution of the angles between cell cytoskeleton ﬁbers inside non-patterned hydrogels (NP, light gray) and in the 3SM (dark gray).
Inside the 3SM moytubes show high degree of alignment (> 75%) following the pattern direction. h) Confocal image of the one structure of the mature 3SM depicting
the cell, showing the presence of MHC positive myotubes (green). Nuclei in blue. Scale bar = 200 μm. i) Fusion index percentage (mean ± standard deviation, **p-
value < 0.01) of the myotubes inside the non-patterned hydrogels (light gray) and in the 3SM (dark gray). (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the Web version of this article.)
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Fig. 4. Monitoring of IL-6 and TNF-α se-
cretion under the eﬀect of chemical stimuli.
Cytokine secretion by ELISA test of a) IL-6
concentration and b) normalized values by
fold change (Treatment/Ctrol), and c) TNF-
α concentration and d) normalized values
by fold change of 2D diﬀerentiated myo-
tubes under the eﬀect of caﬀeine, Dex, and
LPS. Continuous monitoring in integrated
platform of e) IL6 secretion and TNF-α se-
cretion concentration from 3D skeletal
muscle constructs exposed to LPS
(10 μgmL−1) for 24 h. f) Fold change of IL-6
and TNF-α secretion was calculated to assess
responsiveness of 3SM to stimulation with
LPS. Trend of cytokine secretion drawn as a
gray line (IL-6) and a black line (TNF-α).
ANOVA test **p-value< 0.01. Data are
shown by mean ± SD, (n = 4–6).
Fig. 5. a) Picture of the tailored device for the electrical stimulation. b) Lateral view of the device inside the Transwell in a well plate. c) integrated system coupled to
a wave generator and located in a microscope. d) Detail of the connection between coper wires and wave generator. e) Eﬀect of EPS regimes on the cytokine
secretion, f) fold change in IL-6 and TNF-α secretion was calculated to assess responsiveness of 3SM to EPS regimes. Data are shown by mean ± SD. (n=4–6)
p < 0.05.
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imaging of the skeletal muscle tissue during the electrical stimulation
(Fig. 5c). This compact conﬁguration allows the routine use of culture-
well plates inside the incubator.
Previous works have reported that electrical pulse stimulation of in
vitro skeletal muscle induced muscle contractions (Ortega et al., 1039;
Nedachi et al., 2008; Marotta et al., 2004; Ramón-Azcón et al., 2013;
Park et al., 2008; Evers-van Gogh et al., 2015; Banan Sadeghian et al.,
2018). Other works have also reported that intense exercise by skeletal
muscle increases IL-6 expression and secretion, but not of that of TNF-α
(Banan Sadeghian et al., 2018; Bustamante et al., 2014). To obtain an
appropriate stimulation regime with the tailored device, we optimized
the stimulation regime to obtain high IL-6 secretion with a low TNF-α
increase. The skeletal muscle constructs were electrically stimulated
under three voltage regimes 0.25 V, 1 V, and 5 V. We found that elec-
trical stimulations led to a signiﬁcant increase of IL-6 secretion at 0.2
and 1 V, compared to the control, with a maximum level
(0.14 ± 0.02 ngmL−1) by applying 1V (Fig. 5e). No signiﬁcant
changes in TNF-α secretion were found. Ours results suggest a suc-
cessful EPS-evoked contraction of the 3SM, depicted by the increase of
IL-6 expression, without eﬀects on TNF-α release. Normalized values by
fold change (EPS/Ctrol) (Fig. 5f) conﬁrmed the highest IL 6/TNF-α
signal at 1 V, which was ﬁxed for the next experiments.
Once we ﬁxed the EPS regime at 1 V, 1 Hz, and 0.002 s, we at-
tempted to elucidate the time-dependent secretion of IL-6 from the 3D
skeletal muscles tissues. First, we applied continuous EPS for 7 hours, to
mimic endurance exercise and our system allows to detect changes in
secreted IL-6 at low concentrations (0.5–3 ngmL−1). Fig. 6a shows a
signiﬁcant increase of IL-6 from 3 hours after starting EPS, while no
signiﬁcant increase in TNF-α release was observed (Fig. 6b). The eﬀect
of electrical stimulation on the IL-6 expression has been demonstrated
previously in C2C12 myotubes, rat myotubes, with a peak after 2 hours
of EPS, in agreement with our ﬁndings (Evers-van Gogh et al., 2015;
Bustamante et al., 2014; Peake et al., 2015).
Next, we wanted to mimic interrupted exercise by alternating EPS
with relaxed periods and use the biosensor platform to discretize when
3D skeletal muscle releases the cytokines. To this end, we applied sti-
mulation periods of 1 h and relaxation periods of 2 h. First, in the case
of IL-6 we observed lower secretion than in continuous EPS (Fig. 6c),
while the TNF-α secretion kept similar, under 0.5 ngmL−1, as in the
case of continuous EPS (Fig. 6d) without any pattern associated to the
stimulation periods.
We also found an unexpected proﬁle in the IL-6 secretion: a
Fig. 6. Monitoring of a) IL-6 secretion and b) TNF-α secretion under continuous EPS. Monitoring of c) IL6 secretion and d) TNF-α secretion under interrupted EPS.
Arrows indicate EPS and gray background indicates relax period. Fold change increase in e) IL-6 and f) TNF-α secretion was calculated to assess responsiveness of
3SM to electrical stimulation. Results from continuous EPS (dots-line) and interrupted EPS (empty dots-dash line) show an impact on the IL-6 secretion but not on the
TNF-α secretion. Data are shown by mean ± SD. (n= 4–6).
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signiﬁcant increase of secreted IL-6 took place during relaxation periods
after 2 and 3 h, and after 5 and 6 h. To compare both regimes, we
normalized the cytokine secretion by fold change calculation between
stimulated and control samples (EPS/Ctrol). In the case of IL-6, we were
able to measure diﬀerences based on the diﬀerent EPS regimes. During
the 3 ﬁrst hours no diﬀerences are found in terms of fold change, but
after that point, the endurance exercise (continuous EPS) induced
higher IL-6 secretion, while alternate exercise produced to a diﬀerent
proﬁle with lower IL-6 secretion levels and the presence of secretion
peaks (Fig. 6e). As expected, the TNF-α proﬁles were similar with
random tendencies along the time and low fold change (Fig. 6f). As we
showed, the integrated platform allows to monitor the cytokine secre-
tion of the 3D skeletal muscle tissue over the time to discretize the
eﬀect of diﬀerent EPS regimes.
4. Conclusions
In this study, we developed an in vitro integrated platform to
monitor the secretion of inﬂammatory processes related cytokines from
single tissue-based models. When functionalized, magnetic beads were
coupled with a 3D tissue engineered skeletal muscle, and chemical and
electrical stimuli. First, we succeeded in the fabrication of the 3D tissue
engineered skeletal muscle on a porous membrane of Transwells, what
allowed the diﬀusion of the secreted cytokines to the lower compart-
ment. Next, magnetic beads assay developed underneath the mem-
brane, allowed amperometric measurements of IL-6 and TNF-α.
Changes in the concentrations of IL-6 and TNF-α were measured clearly
with limits of detection below of 40 and 20 pgmL−1, respectively.
Through this conﬁguration, secretion processes has been monitored by
the in situ capturing of the released cytokines in a near real-time. Under
proinﬂammatory drug exposure the expected changes in the cytokine
levels were observed, and this eﬀect was further monitored in the 3D
tissue engineered skeletal muscle. In addition, this work showed dif-
ferent time-dependent proﬁles of IL-6 secretion, induced by the elec-
trical stimulation-based contraction. These ﬁndings contribute to the
better understanding roles of IL-6 in muscle related inﬂammation pro-
cess. Therefore, this platform is an attractive candidate for further ap-
plications, since it does not require any complex modiﬁcations. Future
work will involve study of other biomimetic tissues under a wide range
of treatments or disorders, as in vitro test to high sensitivity metabolic
studies.
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